“Science is showing us the path to a future in which new therapeutic options may provide both solutions as well… Read more »
After three years of using the Viaskin Peanut patch in children ages 4 to 11, more than half (52 percent)… Read more »
DBV Technologies has announced that the FDA has agreed to review the company’s Viaskin Peanut patch for potential regulatory approval.… Read more »
The manufacturer of the Viaskin Peanut patch has announced plans to resubmit its biologics license application (BLA) for the therapy… Read more »
We’re learning more about the two therapies to treat peanut allergies that could soon be available in allergist’s offices in… Read more »
With a positive approach, our allergic child does not miss out. In fact, she’s even taking part in the science.
Meet the teenager impacting research as an intern and study participant.
Promising results from Viaskin patch research.